Study for People Enrolled in the New York State Multiple Sclerosis Consortium
Evaluation of Patient-Reported Outcomes Associated with Natalizumab Use in a Real-World Setting
This study enrolls people with Multiple Sclerosis who have already enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC). The purpose of this study is to learn more about the experiences of people with MS who are having a natalizumab infusion.
This study involves a one-time survey. Participants will be NYSMSC members who are having natalizumab infusion at the Jacobs MS Center for Treatment and Research. Study takes place at UB's downtown campus.
To evaluate the association between fatigue and other patient-reported outcomes with natalizumab use in multiple sclerosis patients in the New York State Multiple Sclerosis Consortium
Adults ages 18+.
Have multiple sclerosis.
Are enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC),
Have taken natalizumab for the treatment of MS for at least six months.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the
contact information above or email email@example.com and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality
assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided
in the aforementioned ways, please contact firstname.lastname@example.org.